Pieris Announces Preclinical In Vitro And In Vivo Data For Its Anticalin(r) PRS-080 Hepcidin Antagonist Drug ProgramAnna Ohlden
The development of a novel free hepcidin assay enabled accurate analysis of bioactive hepcidin suppression and elucidation of the observed plasma iron levels after PRS-080-PEG30 administration in vivo . Key Results PRS-080 had a hepcidin-binding affinity of 0.07nM and, after coupling to 30kD PEG...
Key Results PRS-080 had a hepcidin-binding affinity of 0.07nM and, after coupling to 30kD PEG (PRS-080-PEG30), a t 1/2 of 43h in cynomolgus monkeys. Dose-dependent iron mobilization and hepcidin suppression were observed after a single i.v. dose of PRS-080-PEG30 in cynomolgus ...
Antagonistic Anticalin therapeutics have been developed for systemic administration (e.g., PRS-080: anti-hepcidin) or pulmonary delivery (e.g. PRS-060/AZD1402: anti-interleukin [IL]-4-Ra). Moreover, Anticalin proteins allow molecular formatting as bi- and even multispecific fusion proteins, ...